Replimune prices $150M public offering

What's the deal? Replimune priced an underwritten public offering of common stock and pre-funded warrants expected to generate approximately $150 million in gross proceeds. The offering is intended to support the biotechnology company's cancer-immunotherapy programmes.

Read more: The Lethbridge Herald